A phase II multicenter prospective study to evaluate the safety and efficacy of myeloablative-dose treosulfan plus fludarabine (FT14) conditioning regimen in allogeneic hematopoietic stem cell transplantation for AML patients aged 40–65 in first complete remission
Open Access
- 24 June 2026
- journal article
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 61 (9) , 1176-1181
Abstract
Evidences supporting the use of myeloablative-dose Treosulfan combined with Fludarabine remain largely retrospective, with outdated prospective studies available. In this phase II multicenter prospective trial, we evaluated the safety and efficacy of FT14 conditioning regimen in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation in first complete remission.(EudraCT Number:2021-006515-28; Clinical trial number NCT07232953). The study was designed to provide a non-inferior alternative to standard busulfan-containing regimens, which would enable effective transplantation while minimizing toxicity. The primary objective was 1-year Leukemia-free survival (LFS). In total, 82 patients were enrolled in the study with a median follow up of 19.7 months; donor used were matched sibling in 22, matched unrelated 52 and mismatched unrelated in 8 cases, respectively. LFS at 180-day and 365-day were 87.8% and 81.7%, respectively. Cumulative incidence of relapse at 1 year after allo-HSCT was 14.9% with mean time to relapse of 5.6 months. Also, FT14 regimen provided an excellent safety with nearly absent NRM, no cases of septic death, and no cases of primary graft failure. Our study supports the use of FT14 as effective myeloablative conditioning regimen for AML patients aged 40–65 y in first complete remission, especially in patients for whom busulfan based conditioning regimens poses excessive toxic risks.Keywords
This publication has 28 references indexed in Scilit:
- Venetoclax plus decitabine as a bridge to allogeneic haematopoietic stem-cell transplantation in older patients with acute myeloid leukaemia (VEN-DEC GITMO): final report of a multicentre, single-arm, phase 2 trialThe Lancet Haematology, 2024
- GITMO Registry Study on Allogeneic Transplantation in Patients Aged ≥60 Years from 2000 to 2017: Improvements and CriticismsTransplantation and Cellular Therapy, 2022
- A practical guide to chimerism analysis: Review of the literature and testing practices worldwideHuman Immunology, 2021
- Allogeneic stem cell transplant in patients with acute myeloid leukemia and karnofsky performance status score less than or equal to 80%: A study from the acute leukemia working party of the European Society for Blood and Marrow Transplantation (EBMT)Cancer Medicine, 2020
- Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow TransplantationThe Lancet Haematology, 2020
- Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trialThe Lancet Haematology, 2020
- Intravenous Busulfan Compared with Treosulfan-Based Conditioning for Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia: A Study on Behalf of the Acute Leukemia Working Party of European Society for Blood and Marrow TransplantationTransplantation and Cellular Therapy, 2018
- Fluoroquinolone prophylaxis in haematological cancer patients with neutropenia: ECIL critical appraisal of previous guidelinesJournal of Infection, 2018
- Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trialThe Lancet Oncology, 2015
- GVHD pathophysiology: is acute different from chronic?Best Practice & Research Clinical Haematology, 2008